Ozempic 3.0? This drug causes the greatest weight loss by far

Ozempic 3.0?Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it becomes available to the public, a Monday study found.Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide, the active ingredient in Ozempic and Wegovy.Researchers from McGill University in Canada reviewed the results of 26 trials, comprising nearly 15,500 participants, to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.They investigated 12 medications — three that the US Food and Drug Administration (FDA) has approved for weight loss and nine it hasn’t.The drugs mimic GLP-1, a hormone the body naturally produces after eating, so users feel fuller for longer.The analysis found that retatrutide caused the greatest weight loss — participants lost up to 22.1% of their weight after 48 weeks versus people who took a placebo.Eli Lilly’s drug is called “triple G” because it mimics GLP-1, the appetite-suppressing hormone GIP and glucagon, a hormone that helps control blood sugar levels.Phase 3 trials are expected to last until January 2026, so the injection won’t be up for FDA approval for a few years.The Post reached out to a Lilly rep for comment.

The three FDA-approved drugs in the McGill analysis were liraglutide (sold under the brand name Saxenda), semaglutide (Wegovy) and tirzepatide (Zepbound).The review found:A pill form of semaglutide brought similar weight loss as injections, according to the analysis.The FDA approved Novo Nordisk’s semaglutide tablet Rybelsus for adults with diabetes but not for weight management.Among the drugs the FDA hasn’t approved, Lilly’s daily pill orforglipron, Lilly and Innovent’s weekly injection mazdutide and Boehringer Ingelheim’s weekly jab survodutide showed promise.The trials revealed that most pounds are shed early in t...